{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:05:37Z","timestamp":1791331537156,"version":"4.3.1"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1998,4,1]],"date-time":"1998-04-01T00:00:00Z","timestamp":891388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Amphotericin B lipid complex for injection (ABLC) is a suspension of amphotericin B complexed with the lipids\n            <jats:sc>l<\/jats:sc>\n            -\u03b1-dimyristoylphosphatidylcholine (DMPC) and\n            <jats:sc>l<\/jats:sc>\n            -\u03b1-dimyristoylphosphatidylglycerol. ABLC is less toxic than amphotericin B deoxycholate (AmB-d), while it maintains the antifungal activity of AmB-d. Active amphotericin B can be released from ABLC by exogenously added (snake venom, bacteria, or\n            <jats:italic>Candida<\/jats:italic>\n            -derived) phospholipases or by phospholipases derived from activated mammalian vascular tissue (rat arteries). Such extracellular phospholipases are capable of hydrolyzing the major lipid in ABLC. Mutants of\n            <jats:italic>C. albicans<\/jats:italic>\n            that were resistant to ABLC but not AmB-d in vitro were deficient in extracellular phospholipase activity, as measured on egg yolk agar or as measured by their ability to hydrolyze DMPC in ABLC. ABLC was nevertheless effective in the treatment of experimental murine infections produced by these mutants. Isolates of\n            <jats:italic>Aspergillus<\/jats:italic>\n            species, apparently resistant to ABLC in vitro (but susceptible to AmB-d), were also susceptible to ABLC in vivo. We suggest that routine in vitro susceptibility tests with ABLC itself as the test material may not accurately predict the in vivo activity of ABLC and that the enhanced therapeutic index of ABLC relative to that of AmB-d in vivo may be due, in part, to the selective release of active amphotericin B from the complex at sites of fungal infection through the action of fungal or host cell-derived phospholipases.\n          <\/jats:p>","DOI":"10.1128\/aac.42.4.767","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:31:10Z","timestamp":1539045070000},"page":"767-771","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":68,"title":["In Vitro and In Vivo Antifungal Activity of Amphotericin B Lipid Complex: Are Phospholipases Important?"],"prefix":"10.1128","volume":"42","author":[{"given":"Christine E.","family":"Swenson","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->The Liposome Company, Inc., Princeton, New Jersey 08540,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R.","family":"Perkins","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->The Liposome Company, Inc., Princeton, New Jersey 08540,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Roberts","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->The Liposome Company, Inc., Princeton, New Jersey 08540,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->The Liposome Company, Inc., Princeton, New Jersey 08540,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Stevens","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->The Liposome Company, Inc., Princeton, New Jersey 08540,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Stevens","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center and Stanford University, San Jose, California 951282"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Janoff","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->The Liposome Company, Inc., Princeton, New Jersey 08540,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.886"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.3.751-755.1996"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Calderone R. R. Diamond J.-M. Senet J. Warmington S. Filler and J. E. Edwards. 1994. Host cell-fungal cell interactions. J. Med. Vet. Mycol. 32 (Suppl. 1) : 151\u2013168.","DOI":"10.1080\/02681219480000801"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.615"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.10.2144"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jac\/30.3.353","article-title":"Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.","volume":"30","author":"Clemons K. V.","year":"1992","unstructured":"Clemons K. V. Stevens D. A. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30 1992 353 363","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1358\/dot.1996.32.5.379050","article-title":"Amphotericin B lipid complex: review of safety, pharmacokinetics and efficacy.","volume":"32","author":"Dix S. P.","year":"1996","unstructured":"Dix S. P. Wingard J. R. Amphotericin B lipid complex: review of safety, pharmacokinetics and efficacy. Drugs Today 32 1996 411 416","journal-title":"Drugs Today"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.3.1064-1069.1994"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.2.486"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.5.1993-1998.1995"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.16.6122"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150730"},{"key":"e_1_3_1_14_2","unstructured":"Minassian\n              B.\n              Flamm\n              R. K.\n              Whitney\n              R. R.\n              Kunselman\n              L.\n              Bender\n              L.\n              Summerill\n              R.\n              Bonner\n              D. P.\n          Decreased phospholipase activity in C. albicans is associated with increased MICs for amphotericin B lipid complex abstr 847\n          Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy.\n          1990\n          227\n          American Society for Microbiology\n          Washington D.C"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF01104273","article-title":"In vitro and in vivo antifungal activities of liposomal amphotericin B and amphotericin B lipid complex.","volume":"128","author":"Mitsutake K.","year":"1994","unstructured":"Mitsutake K. Kohno S. Miyazaki Y. Noda T. Miyazaki H. Miyazaki T. Kaku M. Koga H. Hara K. In vitro and in vivo antifungal activities of liposomal amphotericin B and amphotericin B lipid complex. Mycopathologia 128 1994 13 17","journal-title":"Mycopathologia"},{"key":"e_1_3_1_16_2","unstructured":"National Committee for Clinical Laboratory Standards\n          NCCLS document M27P vol. 12 no. 25. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standards.\n          1992\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/infdis\/169.5.1057","article-title":"Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis.","volume":"169","author":"Pahls S.","year":"1994","unstructured":"Pahls S. Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J. Infect. Dis. 169 1994 1057 1061","journal-title":"J. Infect. Dis."},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0005-2736(92)90414-H","article-title":"Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity.","volume":"1107","author":"Perkins W. R.","year":"1992","unstructured":"Perkins W. R. Minchey S. R. Boni L. T. Swenson C. E. Popescu M. C. Pasternak R. F. Janoff A. S. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1107 1992 271 282","journal-title":"Biochim. Biophys. Acta"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/00362178285380031","article-title":"Plate method for detection of phospholipase activity in Candida albicans.","volume":"20","author":"Price M. F.","year":"1982","unstructured":"Price M. F. Wilkinson I. D. Gentry L. O. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 20 1982 7 14","journal-title":"Sabouraudia"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.1.188"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.6.4.367"},{"key":"e_1_3_1_22_2","unstructured":"Stevens\n              D. A.\n          Aspergillosis\n          Cecil\u2019s textbook of medicine\n          20th ed.\n              Bennett\n              J. C.\n              Plum\n              F.\n          1996\n          1830\n          1832\n          The W. B. Saunders Co.\n          New York N.Y"},{"key":"e_1_3_1_23_2","unstructured":"Swatek\n              F.\n              Halde\n              C.\n              Rinaldi\n              M. G.\n              Shadomy\n              H. J.\n          Aspergillus species and other opportunistic saprophytic hyaline hyphomycetes\n          Manual of clinical microbiology\n          4th ed.\n              Lennette\n              E. H.\n              Balows\n              A.\n              Hausler\n              W. J.\n              Jr.\n              Shadomy\n              H. J.\n          1985\n          584\n          594\n          American Society for Microbiology\n          Washington D.C"},{"key":"e_1_3_1_24_2","first-page":"1","article-title":"Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states.","volume":"8","author":"Vadas P.","year":"1993","unstructured":"Vadas P. Browning J. Edelson J. Pruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediators 8 1993 1 30","journal-title":"J. Lipid Mediators"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1944"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.bmt.1700664","article-title":"Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.","volume":"19","author":"Wingard J. R.","year":"1997","unstructured":"Wingard J. R. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. 19 1997 343 347","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_27_2","unstructured":"Zar\n              J. H.\n          Biostatistical analysis.\n          1974\n          Prentice-Hall Inc.\n          Englewood Cliffs N.J"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.4.767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.4.767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:50:21Z","timestamp":1645480221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.4.767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,4]]}},"alternative-id":["10.1128\/AAC.42.4.767"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.4.767","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,4]]},"assertion":[{"value":"1997-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}